Broggini M - Search Results

1

The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.

Rulli E, Guffanti F, Caiola E, Ganzinelli M, Damia G, Garassino MC, Piva S, Ceppi L, Broggini M, Marabese M. Rulli E, et al. Among authors: broggini m. Sci Rep. 2016 Dec 14;6:39217. doi: 10.1038/srep39217. Sci Rep. 2016. PMID: 27966655 Free PMC article.

2

DNA Damage Induces p53-dependent Down-regulation of hCHK1.

Damia G, Sanchez Y, Erba E, Broggini M. Damia G, et al. Among authors: broggini m. J Biol Chem. 2001 Apr 6;276(14):10641-5. doi: 10.1074/jbc.M007178200. Epub 2001 Jan 4. J Biol Chem. 2001. PMID: 11152453 Free article.

3

P73a overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line.

Vikhanskaya F, Marchini S, Marabese M, Galliera E, Broggini M. Vikhanskaya F, et al. Among authors: broggini m. Cancer Res. 2001 Feb 1;61(3):935-8. Cancer Res. 2001. PMID: 11221886

4

4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms.

Marchini S, Damia G, Broggini M, Pennella G, Ripamonti M, Marsiglio A, Geroni C. Marchini S, et al. Among authors: broggini m. Cancer Res. 2001 Mar 1;61(5):1991-5. Cancer Res. 2001. PMID: 11280757

5

Cisplatinum and taxol induce different patterns of p53 phosphorylation.

Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, D'incalci M, Broggini M. Damia G, et al. Among authors: broggini m. Neoplasia. 2001 Jan-Feb;3(1):10-6. doi: 10.1038/sj.neo.7900122. Neoplasia. 2001. PMID: 11326311 Free PMC article.

6

p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis.

Vikhanskaya F, Bani MR, Borsotti P, Ghilardi C, Ceruti R, Ghisleni G, Marabese M, Giavazzi R, Broggini M, Taraboletti G. Vikhanskaya F, et al. Among authors: broggini m. Oncogene. 2001 Nov 1;20(50):7293-300. doi: 10.1038/sj.onc.1204896. Oncogene. 2001. PMID: 11704858

7

Characterization of the 5'flanking region of the human Chk1 gene: identification of E2F1 functional sites.

Carrassa L, Broggini M, Vikhanskaya F, Damia G. Carrassa L, et al. Among authors: broggini m. Cell Cycle. 2003 Nov-Dec;2(6):604-9. Cell Cycle. 2003. PMID: 14504477

8

DNA damage induces transcriptional activation of p73 by removing C-EBPalpha repression on E2F1.

Marabese M, Vikhanskaya F, Rainelli C, Sakai T, Broggini M. Marabese M, et al. Among authors: broggini m. Nucleic Acids Res. 2003 Nov 15;31(22):6624-32. doi: 10.1093/nar/gkg869. Nucleic Acids Res. 2003. PMID: 14602923 Free PMC article.

9

Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents.

Damia G, Broggini M. Damia G, et al. Among authors: broggini m. Cell Cycle. 2004 Jan;3(1):46-50. Cell Cycle. 2004. PMID: 14657665 Review.

10

Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53.

Carrassa L, Broggini M, Erba E, Damia G. Carrassa L, et al. Among authors: broggini m. Cell Cycle. 2004 Sep;3(9):1177-81. Epub 2004 Sep 13. Cell Cycle. 2004. PMID: 15326376

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters